Track 05 of 9
Functional GI & Motility
IBS, gastroparesis and neurogastroenterology.
Disorders of gut-brain interaction are being reframed by Rome IV, high-resolution manometry, and the wireless motility capsule. IBS-D management now integrates eluxadoline, rifaximin re-treatment, and low-FODMAP diets, while linaclotide, plecanatide, and tenapanor anchor IBS-C care. EndoFLIP and HRM with the Chicago Classification 4.0 differentiate achalasia subtypes and EGJ outflow obstruction. Gastroparesis sees renewed interest in prucalopride, ghrelin agonists (relamorelin), and gastric peroral endoscopic myotomy (G-POEM). Sessions also cover cyclic vomiting syndrome, rumination, and the central neuromodulator class for visceral hypersensitivity.
Focus areas
- IBS-D: eluxadoline, rifaximin and low-FODMAP evidence
- IBS-C: linaclotide, plecanatide, tenapanor mechanisms and outcomes
- Achalasia subtyping: HRM Chicago Classification 4.0 and EndoFLIP
- Gastroparesis: prucalopride, relamorelin and G-POEM outcomes
- GERD long-term PPI safety and vonoprazan as PCAB alternative
- Central neuromodulators in DGBI: TCAs, SNRIs, atypical agents
- Cyclic vomiting and cannabinoid hyperemesis syndrome